摘要
目的:探讨CXCL趋化因子家族作为肝癌治疗与预后标志物的价值。方法:检索UNIPROT、ONCOMINE、TCGA、GEPIA、TIMER数据库,分析肝癌中异常表达的CXCL因子类型。在KMPLOT网站分析CXCL与肝癌患者不良预后的相关性。使用R语言绘制热图并计算CXCL家族与上皮间质转化(EMT)、免疫因子浸润的相关性。结果:CXCL6、CXCL8、CXCL9、CXCL10在肝癌组织中显著高表达,CXCL2、CXCL12、CXCL14在肝癌中显著低表达。高转录水平CXCL2、CXCL4、CXCL6、CXCL7、CXCL9、CXCL10、CXCL12、低转录水平CXCL6的肝癌患者有更长的生存期。CXCL8与肝癌EMT关系最为密切。CXCL2、CXCL4、CXCL6、CXCL7、CXCL9、CXCL10、CXCL11、CXCL12、CXCL14、CXCL16、CXCL17与常见的6种免疫细胞(B细胞、CD8+T细胞、CD4+T细胞、巨噬细胞、中性粒细胞和树突状细胞)浸润相关。结论:CXCL家族在肝癌组织中具有显著的差异表达,并与肝癌细胞的转移、免疫细胞浸润、预后相关,可作为肝癌临床治疗与预后的潜在标记物。
Objective:To explore the value of chemokine(C-X-C motif)ligand(CXCL)as a marker for treatment and prognosis of liver cancer.Methods:The databases of UNIPROT,ONCOMINE,TCGA,GEPIA,and TIMER were searched,and the types of abnormal expression of CXCLs in HCC were analyzed.The correlation between CXCL and the poor prognosis of patients with liver cancer was analyzed by the KMPLOT website.The R language was used to draw the heat map and calculate the correlation between CXCL and epithelial-mesenchymal transformation(EMT),and infiltration of immune factors.Results:The expression of CXCL6、CXCL8、CXCL9、CXCL10 significantly increased in HCC,while the expression of CXCL2、CXCL12、CXCL14 significantly decreased.Patients with a high transcriptional level of CXCL2、CXCL4、CXCL6、CXCL7、CXCL9、CXCL10、CXCL12 and a low transcriptional level of CXCL6 have a longer survival time.CXCL8 is most tightly related to the EMT of hepatocellular carcinoma.CXCL2、CXCL4、CXCL6、CXCL7、CXCL9、CXCL10、CXCL11、CXCL12、CXCL14、CXCL16、CXCL17 is associated with the infiltration of six common immune cells(B cells,CD8+T cells,CD4+T cells,macrophages,neutrophils,and dendritic cells).Conclusion:There is an abnormal expression of CXCLs in liver cancer,some of which are related to metastasis,immune cell infiltration,and prognosis of liver cancer,providing potential markers for clinical treatment and prognosis of liver cancer.
作者
马莉
杨文娟
马青梅
马梦婷
张娇弟
张倩
刘欣跃
MA Li;YANG Wenjuan;MA Qingmei;MA Mengting;ZHANG Jiaodi;ZHANG Qian;LIU Xinyue(Pharmacogenomics Laboratory,Lanzhou University Second Hospital,Lanzhou 730030,Gansu,China;Laboratory Medicine Center,Lanzhou University Second Hospital,Lanzhou 730030,Gansu,China)
出处
《暨南大学学报（自然科学与医学版）》
CAS
CSCD
北大核心
2022年第1期29-42,共14页
Journal of Jinan University(Natural Science & Medicine Edition)
基金
兰州大学第二医院“萃英科技创新”计划项目(CY2017-MS17)。
